0000899243-21-011749.txt : 20210315 0000899243-21-011749.hdr.sgml : 20210315 20210315211202 ACCESSION NUMBER: 0000899243-21-011749 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210311 FILED AS OF DATE: 20210315 DATE AS OF CHANGE: 20210315 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gollob Jared CENTRAL INDEX KEY: 0001821198 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 21743363 MAIL ADDRESS: STREET 1: C/O KYMERA THERAPEUTICS, INC. STREET 2: 200 ARSENAL YARDS, SUITE 230 CITY: WATERTOWN STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 TECHNOLOGY SQUARE STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 300 TECHNOLOGY SQUARE STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-11 0 0001815442 Kymera Therapeutics, Inc. KYMR 0001821198 Gollob Jared C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 0 1 0 0 Chief Medical Officer Common Stock 2021-03-11 4 M 0 2200 1.31 A 49747 D Common Stock 2021-03-11 4 S 0 4695 60.0509 D 45052 D Common Stock 2021-03-15 4 M 0 7800 1.31 A 52852 D Common Stock 2021-03-15 4 S 0 10305 60.17 D 42547 D Stock Option (Right to Buy) 1.31 2021-03-11 4 M 0 2200 0.00 D 2028-10-31 Common Stock 2200 67807 D Stock Option (Right to Buy) 1.31 2021-03-15 4 M 0 7800 0.00 D 2028-10-31 Common Stock 7800 60007 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.385. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.00 to $60.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Twenty-five percent (25%) of the shares underlying this stock option vested on September 12, 2019 and the remaining shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. /s/ Bruce N. Jacobs, as Attorney-in-Fact 2021-03-15